Biomarkers for cancer sensitivity and uses thereof
Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.
1. A method of predicting sensitivity of a cancer cell to a first anti-cancer agent comprising:
(a) contacting the cancer cell with an effective amount of the anti-cancer agent, wherein the anti-cancer agent comprises TRA-8 or an antibody having the same epitope specificity as TRA-8; and
(b) evaluating the release by the cell of one or more biomarkers selected from the group consisting of fructose-bisphosphate aldolase A (ALDOA), phosphoglycerate kinase 1 (PGK1), peroxiredoxin 1 (PRDX1), and colfilin 1 (COF1), an increase in release by the contacted cell compared to a control cell indicating that the cancer cell is sensitive to the agent.
2. The method of claim 1 , wherein the cancer cell is contacted in vivo.
3. The method of claim 1 , wherein the cancer cell is contacted in vitro.
4. The method of claim 1 , wherein the antibody having the same epitope specificity as TRA-8 is a humanized version of TRA-8.
5. A method of determining an effective dose for an anti-cancer agent comprising:
(a) contacting one or more cancer cells with a plurality of dosages of the anti-cancer agent under conditions that allow cellular release of one or more biomarkers selected from the group consisting of fructose-bisphosphate aldolase A (ALDOA), phosphoglycerate kinase 1 (PGK1), peroxiredoxin 1 (PRDX1), and colfilin 1 (COF1), and histone H4, wherein the anti-cancer agent comprises TRA-8 or an antibody having the same epitope specificity as TRA-8; and
(b) detecting the release at each dosage, higher release rates indicating an effective dosage.
6. The method of claim 5 , wherein the antibody having the same epitope specificity as TRA-8 is a humanized version of TRA-8.
7. The method of claim 5 , wherein at least one cell is contacted with more than one dosage.
8. The method of claim 5 , wherein each cell is contacted with only one dosage.
9. The method of claim 1 , wherein the method further comprises evaluating the release by the cell of histone H4, an increase in release by the contacted cell compared to a control cell indicating that the cancer cell is sensitive to the agent.